Physician profile
Jesi Ramone
NPI 1407819907
$626,825.42
in general payments reported to CMS, 2019-2025
15 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $18K · 2021: $59K · 2022: $79K · 2023: $110K · 2024: $152K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $298K · Travel and Lodging: $41K · Consulting Fee: $17K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $297,618.50 |
| Travel and Lodging | $41,010.24 |
| Consulting Fee | $16,890.00 |
| Food and Beverage | $13,325.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $245,201.79 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Abbvie INC. | $181,462.20 | 2019-2025 | |
| Gilead Sciences, INC. | $146,832.85 | 2019-2025 | Descovy, Epclusa, Biktarvy |
| Janssen Products, LP | $29,220.63 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $21,260.82 | 2019-2023 | Pifeltro |
| Theratechnologies INC. | $1,638.23 | 2019-2022 | |
| Janssen Biotech, INC. | $951.76 | 2019-2023 | Symtuza |
| Medline Industries LP | $89.99 | 2021-2023 | |
| Emd Serono, INC. | $35.19 | 2019-2023 | Serostim |
| Dynavax Technologies Corporation | $31.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.97 | 2021 | |
| Glaxosmithkline, LLC. | $23.42 | 2024 | Shingrix |
| Exact Sciences Corporation | $17.46 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $16.86 | 2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesi Ramone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.